HPLC–DAD protein kinase inhibitor analysis in human serum
- 15 April 2012
- journal article
- Published by Elsevier BV in Journal of Chromatography B
- Vol. 893-894, 77-81
- https://doi.org/10.1016/j.jchromb.2012.02.037
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinibBlood, 2011
- Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometryJournal of Chromatography B, 2010
- A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasNeuro-Oncology, 2009
- A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometryJournal of Chromatography B, 2009
- Phase I Trial of Pazopanib in Patients with Advanced CancerClinical Cancer Research, 2009
- The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2007
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsBlood, 2006
- Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer PatientsDrug Metabolism and Disposition, 2006
- Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off ScheduleClinical Cancer Research, 2004